Alcyone Lifesciences

Alcyone Lifesciences develops a platform of technology that optimizes molecular therapy for the brain.

Alcyone Lifesciences was founded in 2010 to address the unmet needs in treatment of chronic neuropathological conditions. For many neurologic conditions there are identified molecular targets, but the blood brain barrier prevents drugs addressing those targets from reaching diseased brain regions in a controlled and targeted manner. In addition, there is a fundamental need for control and precision in molecular therapy to the CNS. Alcyone Lifesciences has created a best-in-class platform technology which can optimize molecular therapy to the brain